Avid Bioservices – a subsidiary of Peregrine Pharmaceuticals – said it reviewed several suppliers before choosing MilliporeSigma’s technology.
“Avid ran a competitive process in considering which single-use bioreactors to install in our Myford [Myford Road, Tustin] facility,” said president Roger Lias.
“While we carefully reviewed a number of single-use bioreactor options, we chose the MilliporeSigma Mobius 2,000L single-use bioreactor system because it offers technical and ease of use advantages over competing single-use systems,” he told us.
The contract development and manufacturing organisation (CDMO) did not disclose the purchase price.
Avid said it opted for single-use bioreactors in response to growing demand for larger scale, disposable technology.
“This enhancement of our capabilities is just the latest step in our ongoing efforts to expand and diversify our customer base,” said Lias.
The firm told us a percentage of bioreactor capacity had already been allocated to customers.
“With not all capacity currently accounted for we are able to offer prospective new clients a unique short-term opportunity to obtain capacity in a cutting-edge commercial facility,” Lias told us.
Avid said it has room to house one additional 2,000L bioreactor at its Myford Road facility.
A move to single-use?
Lias said single-use technology is a growing trend in the biopharmaceutical industry.
“We believe that there is a clear movement within the industry toward single-use, fully disposable manufacturing” he told us.
Disposable bioreactors improves turnaround times, reduces product cross-contamination risk and decreases capital costs, he said.
“Single-use manufacturing technology helps accelerate moving molecules to market, improves productivity and ensures supply continuity,” he added.